Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The initial study showing linkage of the P50 deficit to the chromosome 15q14 locus of the alpha 7-nicotinic acetylcholine receptor is an example of the potential usefulness of these phenotypes for combined genetic and neurobiological study of schizophrenia.
|
10394470 |
1999 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diminished suppression of the P50 auditory evoked potential is a phenotype used in studies of genetic susceptibility in schizophrenia.
|
15625200 |
2005 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gating of the theta-alpha-frequency oscillatory signal in the paired-click paradigm is more strongly associated with schizophrenia and has significantly higher heritability compared with the traditional P50 gating.
|
18762587 |
2008 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
PPI and P50 gating measures demonstrate substantially increased heritability in schizophrenia families with a higher genetic vulnerability for illness, providing further support for the commonality of genes underlying both schizophrenia and gating measures.
|
26441157 |
2016 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that P50 auditory evoked potentials can be recorded across multiple sites and reliably demonstrate a physiological abnormality in schizophrenia.
|
20382002 |
2010 |
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In persons with bipolar type schizoaffective disorder, CHRNA7 promoter region allelic variants are linked to the capacity to inhibit the P50 auditory evoked potential and thus are associated with a type of illness genetically and biologically more similar to schizophrenia.
|
17192894 |
2007 |
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A number of studies have suggested that the alpha-7-nicotinic receptor D15S1360 polymorphism is associated with schizophrenia and a deficiency in the normal inhibition of the P50 auditory-evoked response.
|
15100704 |
2004 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings provide insight into the mechanisms of P50 suppression in schizophrenia and could potentially improve the performance of early identification and diagnosis of schizophrenia for the earliest intervention.
|
31803031 |
2019 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present findings suggest that COMT Val(108/158)Met polymorphism may not contribute to the risk of schizophrenia and to the P50 deficits, but may contribute to the negative symptoms of schizophrenia among Han Chinese.
|
27315458 |
2016 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The alpha7 nicotinic acetylcholine receptor gene (CHRNA7) is located at 15q13-q14 in a region that is strongly linked to the P50 sensory gating deficit, an endophenotype of schizophrenia and bipolar disorder.
|
18545269 |
2008 |
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Deficits in gating of the P50 response have been shown to segregate with schizophrenia in this sample and may identify carriers of gene(s) predisposing for schizophrenia.
|
8094267 |
1993 |
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Diminished gating of the P50 auditory evoked response to repeated stimuli is a psychophysiological feature of schizophrenia, that is also present in many relatives of patients.
|
1450287 |
1992 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A deficit in sensory gating measured by the suppression of P50 auditory event-related potential (ERP) has been implicated in the biological bases of schizophrenia and some other psychiatric disorders and proposed as a candidate endophenotype for genetic studies.
|
17014995 |
2007 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intriguingly, we observed a significant positive association between ADORA2A upregulation and baseline P50 amplitudes in the schizophrenia group.
|
22705363 |
2012 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast to the Colorado studies in the non-Colorado studies P50 suppression would not qualify as an endophenotype for schizophrenia.
|
17604606 |
2007 |
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We find that P50 and PPI may be influenced by COMT rs4680 polymorphisms in schizophrenia; more excitingly, we find that P50 might be influenced by COMT rs737865 polymorphisms and PPI may be influenced by COMT rs165599 polymorphisms in schizophrenia, and their mutations are associated with the reduction of the risk of P50 or PPI defects in schizophrenia.
|
23598060 |
2013 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The CHRNA7 gene encoding the α7 nicotinic acetylcholine receptor (nAChR) has repeatedly been linked with schizophrenia and the P50 sensory gating deficit.
|
30974230 |
2019 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
All four event-related potential indices are potentially valid endophenotypes for schizophrenia, but P50 suppression and P300 amplitude show the closest genetic relationship to schizophrenia.
|
17475740 |
2007 |
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PERG results showed a significant increase of the P50 implicit time in schizophrenia patients compared with controls (t(55) = 2.1, p < .05, d = 0.55) and a significant increase of the N95 implicit time in schizophrenia patients compared with controls (t(55) = 4.2; p < .001, d = 0.66).
|
31353068 |
2019 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that the P50 sensory gating deficits identified in Chinese patients with schizophrenia may not be involved in the psychopathology of the illness.
|
28606770 |
2017 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results show excess allele sharing for multiple markers in 15q11.2-q25, a chromosomal region previously found linked to a decrease in the normal inhibition of the P50 auditory-evoked response to the second of paired stimuli, a decrease associated with schizophrenia.
|
11803532 |
2001 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Associated with alpha 7 nicotinic acetylcholine receptor (α7 nAChR) dysfunction and shown to be improved with nicotine and α7 nAChR agonists, SG has recently been shown to be improved in low P50 suppressing SCZ patients following acute CDP-choline treatment.
|
30920339 |
2019 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, we observed no P50 suppression deficit in those EOP patients diagnosed with schizophrenia (N = 39).
|
31649298 |
2020 |
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A 2bp deletion in exon 6 of CHRFAM7A, which disrupts the hybrid gene and has previously been associated with P50 deficit, was genotyped in 251 individuals from the Maudsley Family Study of schizophrenia.
|
17012698 |
2006 |
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A deficit in the inhibition of the P50 evoked response to repeated auditory stimuli has been characterized as a neurobiological deficit in schizophrenia.
|
10813805 |
2000 |